Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 3/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.50 |
| ▸ | VCP | P55072 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 5/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5338289 | 0.87 | CDK5 (0.67) | CDK5CDK5R1VCPROCK1DRD4 | |
| SCHEMBL5345415 | 0.76 | CDK5 (0.68) | CDK5CDK5R1ROCK1DRD4DRD2 | |
| SCHEMBL5352789 | 0.75 | CDK5 (0.69) | CDK5CDK5R1ROCK1DRD4ROCK2 | |
| SCHEMBL5346446 | 0.71 | CDK5 (0.75) | CDK5CDK5R1ROCK1 | |
| SCHEMBL5345330 | 0.71 | CDK5 (0.74) | CDK5CDK5R1ROCK1DRD4DRD2 | |
| SCHEMBL5690422 | 0.69 | CDK5 (0.81) | CDK5CDK5R1CNR1ROCK1CNR2 | |
| SCHEMBL5345136 | 0.68 | CDK5 (0.80) | CDK5CDK5R1ROCK1 | |
| SCHEMBL5692115 | 0.67 | CDK5 (1.00) | CDK5CDK5R1ROCK1 | |
| SCHEMBL5347393 | 0.67 | CDK5 (0.78) | CDK5CDK5R1ROCK1ROCK2 | |
| SCHEMBL5347774 | 0.67 | CDK5 (0.78) | CDK5CDK5R1CNR1ROCK1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | CDK5 64/4885CDK5R1 359/4885VCP 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.